Media headlines about AcelRx Pharmaceuticals (NASDAQ:ACRX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AcelRx Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.1954284359543 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

AcelRx Pharmaceuticals traded down $0.03, hitting $4.17, during trading on Monday, according to 27,441 shares of the company traded hands, compared to its average volume of 728,828. The stock has a market capitalization of $215.55 million, a price-to-earnings ratio of -3.79 and a beta of 2.36. AcelRx Pharmaceuticals has a 1 year low of $1.55 and a 1 year high of $5.75. The company has a debt-to-equity ratio of -0.20, a quick ratio of 4.00 and a current ratio of 4.05.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. The company had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $0.78 million. equities research analysts forecast that AcelRx Pharmaceuticals will post -0.81 earnings per share for the current year.

Several analysts have recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of AcelRx Pharmaceuticals in a research report on Monday, June 11th. They set a “buy” rating and a $6.00 price objective on the stock. ValuEngine raised shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Tuesday, May 15th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $5.11.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with's FREE daily email newsletter.